Abstract
The effect of sodium thiosulfate (STS) on the pharmacokinetics and ototoxicity of cisplatin (CDDP) was investigated in guinea pigs. Animals received three intramuscular injections of 7.5 mg/kg CDDP separated by intervals of 5 days with or without STS (1,000 mg/kg) administered intraperitoneally immediately and 1 h after each injection of CDDP or 3 and 6 h later. When administered alone, CDDP caused total outer hair cell (OHC) loss in the basal and second turns of the cochlea. In the group administered CDDP and STS, damage to the OHCs was mild when STS was given concurrently, but was severe when STS was given 3 and 6 h later. Pharmacokinetics measured as free and total platinum (Pt) concentrations in plasma and total Pt concentration in perilymph was not affected after administration of STS with CDDP. These results suggest that an inactive Pt-thiosulfate complex is formed in plasma and is measured as a free Pt component which enters the perilymph via the blood-cochlear barrier. Two possible mechanisms are proposed by which STS reduces ototoxicity: entry of CDDP into target cells such as OHCs and striai marginal cells or binding to intracellular macromolecules of these cells is prevented.
Similar content being viewed by others
References
Abe R, Akiyoshi T, Tsuji H, Baba T (1986) Protection of antiproliferative effect ofcis-diamminedichloroplatinum (II) by sodium thiosulfate. Cancer Chemother Pharmacol 18: 98–100
Abe R, Akiyoshi T, Koba F, Tsuji H, Baba T (1988) ‘Tworoute chemotherapy’ using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies. Eur J Cancer Clin Oncol 24: 1671–1674
Abe R, Akiyoshi T, Baba T (1990) ‘Two-route chemotherapy’ using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoneal cancer. Oncology 47: 422–426
Church MW, Kaltenbach JA, Blakley BW, Burgio DL (1995) The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res 86: 195–203
Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW (1990) Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 10: 353–365
Goel R, Cleary SM, Horton C, Kirmani S, Abramson I, Kelly C, Howell SB (1989) Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 81: 1552–1560
Guastalla JP, Vermorken JB, Wils JA, George M, Scotto V, Nooij M, Bokkel Huinnink WW ten, Dalesio O, Renard J (1994) Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy — a phase II study of the EORTC gynaecological cancer cooperative group. Eur J Cancer 30A: 45–49
Hanneman J, Baumann K (1990) Nephrotoxicity of cisplatin, carboplatin, and transplatin. Arch Toxicol 64: 393–400
Howell SB, Pfeile CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845–851
Howell SB, Pfeile CE, Wung WE, Olshen RA (1983) Intraperitonealcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426–1431
Inoue M, Shimizu C, Shimizu H, Tanizawa O (1991) Neutralizing effect of sodium thiosulfate on antitumor efficacy of cisplatin for human carcinoma xenografts in nude mice. Gynecol Oncol 40: 34–37
Ishizawa M, Taniguchi S, Baba T (1981) Protection by sodium thiosulfate and thiourea against lethal toxicity ofcis-diamminedichloroplatinum (II) in bacteria and mice. Jpn J Pharmacol 31: 883–889
Iwamoto Y, Kawano T, Uozumi J, Aoki K, Baba T (1984) lsTwo-route chemotherapy” using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat Rep 68: 1367–1373
Iwamoto Y, Kawano T, Ishizawa M, Aoki K, Kuroiwa T, Baba T (1985) Inactivation ofcis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits. Cancer Chemother Pharmacol 15: 228–232
Laurell G, Engström B (1989) The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hear Res 38: 27–34
Litterst CL (1984) Cisplatinum: a review, with special references to cellular and molecular interactions. Agents Actions 15: 520–524
Loerer PJ, Einhoen LH (1984) Cisplatin, diagnosis and treatment. Ann Intern Med 100: 704–713
McAlpine D, Johnstone BM (1990) The ototoxic mechanism of cisplatin. Hear Res 47: 191–204
Neijt JP, Bokkel Huinink WW ten, Burg MEL van der, Oosterom AT, Willemse PHB, Vermorken JB, Lindert ACM van, Heintz APM, Aartsen E, Lent M van, Trimbos JB, Meijer AJ de (1991) Long-term survival in ovarian cancer. Eur J Cancer 27: 1367–1372
Otto WC, Brown RD, Gage-White L, Kupetz S, Anniko M, Penny JE, Henley CM (1988) Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs. Hear Res 35: 79–86
Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19–24
Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB (1992) Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 14: 364–371
Sagiyama K, Uozumi J, Aoki K, Baba T (1983) Efficacy of “two-route chemotherapy” using intra-arterial cisplatin and iv sodium thiosulfate, its antidote, in rat bladder tumor. Cancer Treat Rep 67: 567–572
Saito T, Aran J-M (1994) X-ray microanalysis and ion microscopy of guinea pig cochlea and kidney after cisplatin treatment. ORL 56: 310–314
Saito T, Aran J-M (1994) Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL 56: 315–320
Saito T, Manabe Y, Honda N, Yamada T, Yamamoto T, Saito H (1995) Semiquantitative analysis by scanning electron microscopy of cochlear hair cell damage by ototoxic drugs. Scanning Microsc 9: 271–281
Saito T, Manabe Y, Saito H (1995) Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin. ORL 57: 250–255
Schweitzer VG (1993) Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103 [Suppl 59]: 1–52
Singh G (1989) A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicology 58: 71–80
Smith IE, Talbot DC (1992) Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer 65: 787–793
Uozumi J, Sagiyama K, Aoki K, Iwamoto Y, Baba T (1983) Effectiveness of ‘two-route chemotherapy’, using cisplatin and its antidote, sodium thiosulfate, on lifespan of rats bearing metastatic liver tumors. Cancer Treat Rep 67: 1067–1074
Uozumi J, Ishizawa M, Iwamoto Y, Baba T (1984) Sodium thiosulfate inhibitscis-diamminedichloroplatinum (II) activity. Cancer Chemother Pharmacol 13: 82–85
Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM (1983) Ototoxicity ofcis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19: 53–58
Vermorken JB, Vijgh WJF van der, Klein I, Gall HE, Groeningen CJ van, Hart GAM, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39: 136–144
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saito, T., Zhang, Z.J., Manabe, Y. et al. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur Arch Otorhinolaryngol 254, 281–286 (1997). https://doi.org/10.1007/BF02905989
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02905989